CAS Medical Systems, Inc. Discloses Anticipated 21% Increase in Revenue for First Quarter 2001 and Discusses Outlook for Fiscal 2001

Apr 10, 2001, 01:00 ET from CAS Medical Systems, Inc.

    BRANFORD, Conn., April 10 /PRNewswire/ --
 CAS Medical Systems, Inc. (OTC Bulletin Board:   CAMY) today disclosed
 anticipated results of operations for the first quarter of 2001.  Total
 revenues are expected to be approximately $3,650,000 compared to
 $3,003,000 for the same quarter of 2000, which would represent a 21% increase.
 The expected increase in sales can be attributed largely to the Apnea Monitor
 product line acquired from a subsidiary of Mallinckrodt, Inc. in late 2000.
     Net income for this period is expected to be approximately $35,000 as
 compared to $222,000 for the similar period in 2000.  The lower income
 expectation is primarily caused by start up costs relating to the acquisition
 from Mallinckrodt, along with certain changes to our product mix.  Complete
 and definitive financial information for the first quarter will be released in
 the Company's Quarterly Report on Form 10-QSB to be filed with the SEC not
 later than May 14, 2001.
     The Company reports that it has completed the transfer of all operations
 for the former Mallinckrodt product line to its facility in Branford, CT.
 Louis P. Scheps, President and CEO of CAS Medical Systems, Inc. stated, "We
 are still in the process of hiring and training personnel to support the
 manufacturing, sales and service of this significant product line.  We
 anticipate that this will be complete by the end of second quarter."
     CAS reports that it is strengthening its organization by adding new
 skilled personnel in the areas of marketing and sales so as to support its
 needs as it grows.  Mr. Scheps stated, "We continue to be active in the area
 of product development, as well as in seeking out opportunities for product
 acquisitions and alliances.  Sales in our OEM businesses and EMS monitor area
 continue to be strong and show signs of growth for the coming year while our
 neonatal business is under continued price pressure."
     Mr. Scheps continued, "It is anticipated that 2001 will be another record
 year for CAS Medical Systems with expected revenues of between $15,000,000 to
 $17,000,000.  Though it is difficult to accurately forecast income for 2001
 due to the impact of the absorption of the new Mallinckrodt product line, as
 well as the increased cost relating to the growth of our organization, we
 still feel confident that this will be our twelfth consecutive year of
 profitability."
     Founded in 1984, CAS Medical Systems, Inc. designs, manufactures and
 markets medical products, specifically blood pressure measurement equipment,
 apnea monitoring equipment and products for neonatal intensive care.  The
 Company's products are designed to improve the quality of patient care and
 provide exceptional value and performance.  With a reputation for the highest
 quality products available in the markets it serves, CAS' products are used by
 clinicians worldwide.
 
     This press release contains forward-looking statements that involve risks
 and uncertainties.  Actual results could vary materially from the description
 contained herein due to many factors, including but not limited to, the
 customer acceptance of the products in the market, the introduction of
 competitive products and product development, commercialization and
 technological difficulties, and other risks detailed in the Company's
 Securities and Exchange Commission filings.
 
 

SOURCE CAS Medical Systems, Inc.
    BRANFORD, Conn., April 10 /PRNewswire/ --
 CAS Medical Systems, Inc. (OTC Bulletin Board:   CAMY) today disclosed
 anticipated results of operations for the first quarter of 2001.  Total
 revenues are expected to be approximately $3,650,000 compared to
 $3,003,000 for the same quarter of 2000, which would represent a 21% increase.
 The expected increase in sales can be attributed largely to the Apnea Monitor
 product line acquired from a subsidiary of Mallinckrodt, Inc. in late 2000.
     Net income for this period is expected to be approximately $35,000 as
 compared to $222,000 for the similar period in 2000.  The lower income
 expectation is primarily caused by start up costs relating to the acquisition
 from Mallinckrodt, along with certain changes to our product mix.  Complete
 and definitive financial information for the first quarter will be released in
 the Company's Quarterly Report on Form 10-QSB to be filed with the SEC not
 later than May 14, 2001.
     The Company reports that it has completed the transfer of all operations
 for the former Mallinckrodt product line to its facility in Branford, CT.
 Louis P. Scheps, President and CEO of CAS Medical Systems, Inc. stated, "We
 are still in the process of hiring and training personnel to support the
 manufacturing, sales and service of this significant product line.  We
 anticipate that this will be complete by the end of second quarter."
     CAS reports that it is strengthening its organization by adding new
 skilled personnel in the areas of marketing and sales so as to support its
 needs as it grows.  Mr. Scheps stated, "We continue to be active in the area
 of product development, as well as in seeking out opportunities for product
 acquisitions and alliances.  Sales in our OEM businesses and EMS monitor area
 continue to be strong and show signs of growth for the coming year while our
 neonatal business is under continued price pressure."
     Mr. Scheps continued, "It is anticipated that 2001 will be another record
 year for CAS Medical Systems with expected revenues of between $15,000,000 to
 $17,000,000.  Though it is difficult to accurately forecast income for 2001
 due to the impact of the absorption of the new Mallinckrodt product line, as
 well as the increased cost relating to the growth of our organization, we
 still feel confident that this will be our twelfth consecutive year of
 profitability."
     Founded in 1984, CAS Medical Systems, Inc. designs, manufactures and
 markets medical products, specifically blood pressure measurement equipment,
 apnea monitoring equipment and products for neonatal intensive care.  The
 Company's products are designed to improve the quality of patient care and
 provide exceptional value and performance.  With a reputation for the highest
 quality products available in the markets it serves, CAS' products are used by
 clinicians worldwide.
 
     This press release contains forward-looking statements that involve risks
 and uncertainties.  Actual results could vary materially from the description
 contained herein due to many factors, including but not limited to, the
 customer acceptance of the products in the market, the introduction of
 competitive products and product development, commercialization and
 technological difficulties, and other risks detailed in the Company's
 Securities and Exchange Commission filings.
 
 SOURCE  CAS Medical Systems, Inc.